Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Spatiotemporal evolution of venous narrowing in acute MS lesions.

Eisele P, Szabo K, Ebert A, Brueck W, Platten M, Gass A.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e440. doi: 10.1212/NXI.0000000000000440. eCollection 2018 Mar.

2.

Mouse model for molybdenum cofactor deficiency type B recapitulates the phenotype observed in molybdenum cofactor deficient patients.

Jakubiczka-Smorag J, Santamaria-Araujo JA, Metz I, Kumar A, Hakroush S, Brueck W, Schwarz G, Burfeind P, Reiss J, Smorag L.

Hum Genet. 2016 Jul;135(7):813-26. doi: 10.1007/s00439-016-1676-4. Epub 2016 May 2.

PMID:
27138983
3.

Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.

Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, Grose C, Carpenter JE, Rempel A, Bos N, Kandasamy B, Lear-Kaul K, Holmes DB, Bennett JL, Cohrs RJ, Mahalingam R, Mandava N, Eberhart CG, Bockelman B, Poppiti RJ, Tamhankar MA, Fogt F, Amato M, Wood E, Durairaj V, Rasmussen S, Petursdottir V, Pollak L, Mendlovic S, Chatelain D, Keyvani K, Brueck W, Nagel MA.

Neurology. 2015 May 12;84(19):1948-55. doi: 10.1212/WNL.0000000000001409. Epub 2015 Feb 18.

4.

Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration.

Keric N, Maier GS, Samadani U, Kallenberg K, Dechent P, Brueck W, Heuer J, Rohde V.

Transl Stroke Res. 2012 Jul;3(Suppl 1):88-93. doi: 10.1007/s12975-012-0188-3. Epub 2012 May 26.

5.

Lesion pathology predicts response to plasma exchange in secondary progressive MS.

Zettl UK, Hartung HP, Pahnke A, Brueck W, Benecke R, Pahnke J.

Neurology. 2006 Oct 24;67(8):1515-6. No abstract available.

PMID:
17060593
6.

Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation.

Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, Hemmer B, Sommer N.

J Neuroimmunol. 2006 Oct;179(1-2):1-8. Epub 2006 Aug 10.

PMID:
16904192
7.

Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.

Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M.

Brain. 2005 Nov;128(Pt 11):2689-704. Epub 2005 Aug 25.

PMID:
16123145
8.

Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions.

Höftberger R, Aboul-Enein F, Brueck W, Lucchinetti C, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H.

Brain Pathol. 2004 Jan;14(1):43-50.

PMID:
14997936
9.

Two brothers with findings resembling congenital intrauterine infection-like syndrome (pseudo-TORCH syndrome).

Knoblauch H, Tennstedt C, Brueck W, Hammer H, Vulliamy T, Dokal I, Lehmann R, Hanefeld F, Tinschert S.

Am J Med Genet A. 2003 Jul 15;120A(2):261-5.

PMID:
12833411
10.

A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.

Harroch S, Furtado GC, Brueck W, Rosenbluth J, Lafaille J, Chao M, Buxbaum JD, Schlessinger J.

Nat Genet. 2002 Nov;32(3):411-4. Epub 2002 Sep 30.

PMID:
12355066
11.

Multiple sclerosis: lessons from neuropathology.

Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H.

Semin Neurol. 1998;18(3):337-49. Review.

PMID:
9817538

Supplemental Content

Loading ...
Support Center